LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers hope ...

ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE ® trial of ...

Credit: Shutterstock / ChiccoDodiFC. Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study (NCT05693142), which is examining its investigational gene ...

US gene therapy company Regenxbio (Nasdaq: RGNX) has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an ...

Interim data from the Phase 1/2 part of the trial, which is sponsored by RGX-202’s developer Regenxbio, also indicate that RGX-202 appears to be working as intended, robustly increasing the production ...

De­spite pi­o­neer­ing RNAi drug de­vel­op­ment and get­ting four ther­a­pies ap­proved, Al­ny­lam still isn’t prof­itable.

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has shared new interim data from its ongoing Phase I/II AFFINITY DUCHENNE® trial, evaluating RGX-202, an investigational gene therapy for Duchenne ...

Re­genxbio has bio­mark­er da­ta on the first pa­tient younger than 4 years old dosed with its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py, show­ing that the pa­tient … ...

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy ...

(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...

ROCKVILLE, Md., March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY ...